Duygu Yilmaz
Director, RNA Therapeutics & Translational Science Aerska
Seminars
- Aerska is developing siRNAs for CNS indications
- Aerska’s lead program is APP Program for the treatment of Alzheimer’s Disease
- Aerska will be presenting their approach in siRNA lead development to identify a potent sequence and the delivery strategy to reach CNS
This session is designed to equip experienced drug developers and multidisciplinary teams with the technical knowledge required to enter the CNS oligonucleotide space. Whether you have recently transitioned from peptides or small molecules, are exploring oligonucleotides for CNS targets, or want your team to have a shared understanding, this session provides a practical foundation. Attendees will gain a clear understanding of oligonucleotide chemistry, pharmacokinetics, cellular uptake, and CNS-specific challenges. The session will cover key considerations in target selection, delivery strategies, translational modelling, and biomarker integration, providing a practical framework to evaluate and advance CNS oligonucleotide programmes.
